Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
38.14 USD | -6.00% | -9.85% | -0.57% |
May. 30 | Baird Starts Astrana Health With Outperform Rating, $54 Price Target | MT |
May. 16 | Transcript : Astrana Health, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 10:00 AM |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- With a 2024 P/E ratio at 27.18 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.57% | 1.98B | D+ | ||
+25.45% | 88.38B | C+ | ||
-22.84% | 77.56B | B- | ||
+8.73% | 28.74B | C+ | ||
+6.91% | 18.45B | A- | ||
-14.57% | 16.57B | B | ||
+2.56% | 15.81B | A- | ||
+78.14% | 13.65B | C- | ||
+80.13% | 13.06B | C+ | ||
+3.95% | 12.61B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ASTH Stock
- Ratings Astrana Health, Inc.